inVentiv Health announces 'significant' investment, cancels IPO

By Melissa Fassbender

- Last updated on GMT

(Image: iStock)
(Image: iStock)
With the on-boarding of the global private equity investor, Advent International, inVentiv has canceled its previously planned IPO.

Per the agreement, announced today, Advent International will make a material equity investment in inVentiv Health, valuing the company at $3.8bn on a cash-free, debt-free basis.

The transaction is expected to be completed in the fourth quarter of 2016.

Michael Bell, Chairman and Chief Executive Officer of inVentiv Health, commented in a press release that the investment will allow the company to navigate the “increasingly complex scientific and regulatory environment​.”

inVentiv did not respond to a request for comment.

According to the company, "As a result of signing the transaction, inVentiv Group Holdings, Inc., the indirect parent company of inVentiv Health, does not plan to pursue an initial public offering of its common stock at this time​."

As Outsourcing-Pharma.com previously reported​, inVentiv Group Holding filed an S1 with the Securities and Exchange Commission (SEC) in April of this year. The company was seeking to raise $100m by listing on either the New York Stock Exchange or the NASDAQ Global Market.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars